Drug Profile
Bevacizumab biosimilar - Cipla BioTec
Alternative Names: CBT-124Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Cipla BioTec
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Non-small cell lung cancer
Most Recent Events
- 07 Dec 2022 No development reported - Phase-III for Non-small cell lung cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in Bulgaria, Hungary (IV)
- 28 May 2020 No recent reports of development identified for preclinical development in Cancer in Australia (IV, Infusion)
- 28 Jul 2019 No recent reports of development identified for phase-I development in Cancer(In volunteers) in New Zealand (IV, Infusion)